Hoth Therapeutics, Inc. (HOTH)

USD 0.79

(-3.05%)

Market Cap (In USD)

5.48 Million

Revenue (In USD)

-

Net Income (In USD)

-7.84 Million

Avg. Volume

3.77 Million

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.58-1.73
PE
-
EPS
-
Beta Value
0.844
ISIN
US44148G2049
CUSIP
44148G105
CIK
1711786
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Robb Knie
Employee Count
-
Website
https://www.hoththerapeutics.com
Ipo Date
2019-02-15
Details
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-003 to treat inflammatory bowel diseases, as well as acne and psoriasis; HT-004 for treatment of asthma and allergies using inhalational administration; HT-006 to treat lung diseases resulting from bacterial infections; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; the University of Maryland; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc.; Zylö Therapeutics, Inc., and the University of Cincinnati. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.

More Stocks